预处理的IL-33介质干细胞通过改善M2巨细胞的聚合和极化来减轻急性肝衰竭

Hui Yuan1, Yuwen Li2, Zihao Kong3

  • 1Department of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Stem cells international
|October 31, 2024
PubMed
概括

介素-33 (IL-33) 增强了中酶体干细胞 (MSCs),用于治疗急性肝衰竭 (ALF). IL-33的预处理改善了MSC的迁移,并促进了抗炎M2巨细胞的两极分化,有助于肝脏的修复.